recent projects

BridgePoint Bio delivers technology educational series for Caring Cross

Caring Cross is a non-profit company focused on expanding patient access to curative cell therapies, including CAR-T and HIV cell therapies.

Throughout 2023 and 2024, Bridgepoint Bio is providing a customized education series for the Caring Cross community. We design, build and present these monthly seminars. Topics include the biology of AAV gene therapies and lentiviral cell therapies. We explore the scientific, clinical and commercial issues of these transformative therapies.

The courses are designed to be engaging and informative for a broad, international audience. The Caring Cross audience includes healthcare providers, patient advocates and biotech industry employees.

The purpose of our educational series is to:

  • Explore the scientific, clinical and commercial challenges facing cell and gene therapies

  • Train new biotech employees in this sector

  • Provide outreach and understanding of these therapies to the international, healthcare community

Hit the button below to become a Caring Cross member. Membership is free and provides access to their educational seminars.

BridgePoint Videos

Videos below are sample excerpts from larger courses that we design for clients.

These videos provide biological context around recent news in advanced therapies. We highlight key takeaways and insights surrounding new clinical or commercial developments in genetic medicine.

How does gene editing work?

Casgevy is the first gene editing drug to receive FDA approval. I explain gene editing in the context of Casgevy for Sickle Cell Disease.

Delivery of gene editing medicine (1/3)

We have developed the capacity to precisely edit DNA, now we need to master the art of deploying this cargo into the right cells in a patient’s body. I introduce this topic and describe how viral vectors and ‘naked cargo’ could be used to deliver this medicine.

Accidental germline gene editing?

Designing a gene editing clinical trial requires a thoughtful approach towards the accidental editing of sperm and egg cells. The consensus opinion among governing bodies… is that we are comfortable delivering edits to adult cells, but we are not ready to deliver gene edits into germ cells.